Commentary: Anti-vascular endothelial growth factor therapies in vitreo-retina practice: Biosimilars versus biologics.
作者信息
Anantharaman Giridhar
机构信息
Giridhar Eye Institute, Cochin, Kerala, India.
出版信息
Indian J Ophthalmol. 2021 Feb;69(2):358-359. doi: 10.4103/ijo.IJO_40_21.
Abstract
摘要
相似文献
1
Commentary: Anti-vascular endothelial growth factor therapies in vitreo-retina practice: Biosimilars versus biologics.评论：玻璃体内视网膜治疗中的抗血管内皮生长因子疗法：生物类似药与生物制品的对比
Indian J Ophthalmol. 2021 Feb;69(2):358-359. doi: 10.4103/ijo.IJO_40_21.
2
Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey.抗血管内皮生长因子（anti-VEGF）生物类似药使用变化趋势：来自印度玻璃体视网膜学会抗 VEGF 生物类似药调查的见解。
Indian J Ophthalmol. 2021 Feb;69(2):352-356. doi: 10.4103/ijo.IJO_2703_20.
3
Commentary: Use of biosimilars for retinal diseases in India: Challenges and concerns.评论：印度视网膜疾病生物类似药的使用：挑战与担忧
Indian J Ophthalmol. 2021 Feb;69(2):357-358. doi: 10.4103/ijo.IJO_39_21.
4
Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.药师在实践中实施治疗性肿瘤生物类似药的观点和考虑因素。
Am J Health Syst Pharm. 2019 Oct 15;76(21):1725-1738. doi: 10.1093/ajhp/zxz190.
5
Biosimilars for Retinal Diseases: An Update.视网膜疾病的生物类似药：最新进展
Am J Ophthalmol. 2021 Apr;224:36-42. doi: 10.1016/j.ajo.2020.11.017. Epub 2020 Dec 9.
6
Efficacy and Safety of Anti-cancer Biosimilars Compared to Reference Biologics in Oncology: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.抗癌生物类似药与肿瘤学参照生物制剂相比的疗效和安全性：随机对照试验的系统评价和荟萃分析。
BioDrugs. 2019 Aug;33(4):357-371. doi: 10.1007/s40259-019-00358-1.
7
A clinician's guide to biosimilars in oncology.肿瘤治疗中生物类似药的临床应用指南
Cancer Treat Rev. 2016 May;46:73-9. doi: 10.1016/j.ctrv.2016.04.003. Epub 2016 Apr 21.
8
A Clinical Review of Biosimilars Approved in Oncology.肿瘤学中获批生物类似药的临床综述
Ann Pharmacother. 2021 Mar;55(3):362-377. doi: 10.1177/1060028020944596. Epub 2020 Jul 26.
9
The brave new world of biosimilars ('similar biologics') in India.印度生物类似药（“类似生物制品”）的全新世界。
Postgrad Med J. 2017 Oct;93(1104):577-579. doi: 10.1136/postgradmedj-2017-134806. Epub 2017 May 25.
10
Use of Biologics and Biosimilars in Rheumatology.生物制剂和生物类似药在风湿病学中的应用。
J Assoc Physicians India. 2017 May;65(5 Suppl):9-14.
引用本文的文献
1
Treatment Landscape of Macular Disorders in Indian Patients with the Advent of Razumab™ (World's First Biosimilar Ranibizumab): A Comprehensive Review.随着Razumab™（全球首款生物类似药雷珠单抗）的问世，印度黄斑疾病患者的治疗前景：一项全面综述
Ophthalmol Ther. 2021 Sep;10(3):431-443. doi: 10.1007/s40123-021-00362-1. Epub 2021 Jun 21.
本文引用的文献
1
Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey.抗血管内皮生长因子（anti-VEGF）生物类似药使用变化趋势：来自印度玻璃体视网膜学会抗 VEGF 生物类似药调查的见解。
Indian J Ophthalmol. 2021 Feb;69(2):352-356. doi: 10.4103/ijo.IJO_2703_20.
2
A Multicenter, Retrospective Study (RE-ENACT 2) on the Use of Razumab™ (World's First Biosimilar Ranibizumab) in Wet Age-Related Macular Degeneration.一项关于Razumab™（全球首款雷珠单抗生物类似药）用于湿性年龄相关性黄斑变性的多中心回顾性研究（RE-ENACT 2）
Ophthalmol Ther. 2020 Mar;9(1):103-114. doi: 10.1007/s40123-019-00228-7. Epub 2019 Dec 27.
3
Understanding biosimilars and its regulatory aspects across the globe: an ophthalmology perspective.理解生物类似药及其在全球的监管方面：眼科视角。
Br J Ophthalmol. 2020 Jan;104(1):2-7. doi: 10.1136/bjophthalmol-2019-314443. Epub 2019 Jul 17.
4
Biosimilars in ophthalmology: "Is there a big change on the horizon?".眼科生物类似药：“即将迎来重大变革吗？”
Clin Ophthalmol. 2018 Oct 24;12:2137-2143. doi: 10.2147/OPTH.S180393. eCollection 2018.
5
Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.玻璃体内注射阿柏西普治疗新生血管性年龄相关性黄斑变性：VIEW 研究的 96 周结果。
Ophthalmology. 2014 Jan;121(1):193-201. doi: 10.1016/j.ophtha.2013.08.011. Epub 2013 Sep 29.
6
Ranibizumab for neovascular age-related macular degeneration.雷珠单抗用于治疗新生血管性年龄相关性黄斑变性。
N Engl J Med. 2006 Oct 5;355(14):1419-31. doi: 10.1056/NEJMoa054481.
7
Pegaptanib for neovascular age-related macular degeneration.培加他尼用于治疗新生血管性年龄相关性黄斑变性。
N Engl J Med. 2004 Dec 30;351(27):2805-16. doi: 10.1056/NEJMoa042760.
Zotero 插件